A storied MNC exits its listed Indian subsidiary, a homegrown PE firm takes majority control — and the deal quietly rewrites the rules of who owns India's pharma market.
At 4:20 PM on 29 July 2026, the 245th board meeting of Novartis India Limited convened in Mumbai. Eighty minutes later, it was over. A Swiss pharmaceutical giant had ceased to be a promoter in India's listed markets, six directors had resigned, six new ones had been appointed — including a new MD & CEO — and one of India's most established PE firms had taken the wheel of a listed pharmaceutical company. In the language of regulatory filings, it was a "change in control." In the language of the Indian pharma industry, it was the latest chapter of a story that has been quietly unfolding for a decade.
Novartis AG sold its entire 70.68% stake in Novartis India Limited in a deal worth approximately ₹1,446 crore to a consortium led by private equity firm ChrysCapital, along with WaveRise Investments Limited and Two Infinity Partners. (One source cites the consideration at ₹1,376.8 crore; the ₹1,446 crore figure is more widely corroborated across filings and has been used throughout.)
The acquisition was executed pursuant to a Share Purchase Agreement dated February 19, 2026, giving both sides five months to satisfy regulators before closing.
The consortium acquired the shares at ₹860.64 per share, described as a 3.6% premium, and Novartis India's stock surged nearly 18% after the Swiss parent announced the sale. The market, in other words, had priced in the transaction well before the ink dried.
Under SEBI's takeover regulations — the rules governing what happens when someone acquires a large chunk of a listed company — any acquirer crossing 25% must make an open offer: a public invitation for minority shareholders to sell their shares at the same price. The open offer covered up to 26% of voting share capital at ₹860.64 per share, for up to 64,19,608 shares, with total consideration up to ₹552.49 crore payable in cash.
In practice, almost no one tendered. The open offer concluded with the acceptance of only 40 shares at ₹860.64 per share. The shareholding of public shareholders adjusted marginally to 72,40,077 shares, representing 29.32% of the voting share capital. The reason is straightforward: by the time the offer opened, Novartis India had hit an all-time high of ₹1,588.40 on 1 June 2026 — well above the ₹860.64 offer price. Rational shareholders simply sold in the market instead.
The transition was formalised at the 245th board meeting held on 29 July 2026, which commenced at 4:20 PM and concluded at 5:40 PM. The board also approved critical commercial agreements with Novartis AG, including a royalty-free licence for the Tegrital trademark and a five-year distribution agreement for pharmaceutical products — a provision that matters more than it sounds, as we'll see.
Before the strategy, a structural point that is easy to miss.
Novartis has two subsidiaries in India: Novartis India Limited (NIL), the listed company with its legacy portfolio, and Novartis Healthcare Private Limited (NHPL), an unlisted entity. The ownership of the publicly listed entity has changed, while Novartis AG stated it would continue its India operations through Novartis Healthcare Private Limited — a distinction central to how the company positioned the divestment, alongside its stated therapeutic priorities including oncology, cardio-renal-metabolic diseases, immunology, and neuroscience.
This is a clean surgical separation. The parent retains the cutting-edge drug pipeline; it hands the legacy-brand trading business to a domestic buyer.
So what does the legacy business actually look like? Novartis India reported revenue from operations of ₹354.33 crore for FY2026 and profit of ₹93.18 crore, compared to FY2025 revenue of ₹356.27 crore and profit of ₹100.90 crore.
A 26% net margin on essentially flat revenues is the financial profile of a business with good brands that isn't growing. Which is precisely what makes it interesting to a PE firm with a specific plan.
NIL's portfolio spans pain management, calcium supplementation, and neurology — Voveran (diclofenac, a commonly prescribed painkiller), Calcium Sandoz, and Tegrital (used in epilepsy and bipolar disorder). These are not obscure names. They carry something money cannot easily buy: doctor familiarity and patient recall built over thirty-plus years.
There is, however, one caveat to the flat-revenue story. Novartis India reported a 16.6% rise in net profit and revenue from operations increasing 18.6% to ₹1,038.1 million from ₹875.5 million in the corresponding period of the previous year, for the quarter ended June 30, 2026 (per a single reported source; these figures have not been independently corroborated). One strong quarter doesn't reverse a multi-year trend, but ChrysCapital takes control of a business that appears to be moving in the right direction.
The simplest explanation is the most accurate: what Novartis the global company cares about — oncology, immunology, cardio-renal-metabolic diseases — has very little to do with selling painkillers and calcium supplements in semi-urban India.
Global MNCs find it easier to compete in India while drugs are under patent. Once patents expire, Indian generics manufacturers can make the same molecule more cheaply, without a Swiss parent's compliance overhead. NIL's portfolio is composed almost entirely of such off-patent molecules.
Then there are price controls. India's National List of Essential Medicines periodically brings drugs under government-regulated ceiling prices, compressing margins without warning. GlaxoSmithKline India's profits plunged by over 70% in the third quarter of FY2023-24 after price caps hit two marquee antibiotic brands following their inclusion in the revised list. Some MNCs are also wary of India's IP regime, which discourages patent evergreening and permits compulsory licensing — allowing a third party to manufacture a drug without the patent holder's consent.
Novartis is following a trail blazed by others. Sanofi has exited large parts of its Indian pharma portfolio — nutritionals went to Universal Nutriscience, Soframycin to Encube. Pfizer, AstraZeneca, and GSK have all reduced manufacturing, sales, and marketing operations in India over recent years.
As Ranjit Shahani, former vice-chairman of Novartis India, put it: "Faced with regulatory headwinds, IPR challenges and pressure from the parent on generating profits/value from their Indian businesses, most MNCs are reevaluating their strategy for the Indian market."
The exit is rational. The harder question is: what does the buyer do with what's left?
ChrysCapital, India's largest homegrown private equity firm, closed its tenth fund — ChrysCapital X — at $2.2 billion, the biggest India-focused PE fund ever raised, a sharp rise from its $1.35 billion predecessor. The Novartis India deal is funded from this vehicle. ChrysCapital aims to build NIL into a leading branded-generics platform for the Indian market, and the transaction marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector.
That last detail is significant. ChrysCapital has backed pharma for years as a minority shareholder. "Their biggest successes — Mankind, Eris Lifesciences, Intas and other pharma-healthcare bets — came after they developed deep domain expertise in those areas, which have now become their defining edge," as one investment banker put it. The firm has deployed over $5.5 billion across 110 portfolio companies and realised $7.8 billion across 80 exits with a reported 3.0x return on investment.
Those were minority bets — you ride along, you don't steer. This time, ChrysCapital is in the driver's seat. The playbook for a control deal like this typically has three levers:
Lever 1 — Brand monetisation. NIL's brands generate consistent cash flows even on flat revenues. A PE owner without a Swiss parent's overhead can reinvest more aggressively in brand building: detailing (sending medical representatives to doctors), co-promotion deals, and line extensions.
Lever 2 — Licensing and distribution. The board has already secured a five-year distribution agreement with Novartis AG and a royalty-free licence for the Tegrital trademark. That's not a goodbye — it's a structured transition that keeps product supply intact while NIL establishes independence under a new corporate identity.
Lever 3 — Bolt-on acquisitions. With a $2.2 billion fund and ₹1,446 crore deployed, there is firepower to acquire complementary branded-generics portfolios from other MNCs also weighing their options. The sector is full of such candidates — and ChrysCapital, having watched the MNC retreat from the inside for years, knows exactly where to look.
The bull case is real. So are the risks.
The growth problem may be structural. NIL's revenues were essentially flat from FY25 (₹356.27 crore) to FY26 (₹354.33 crore). That reflects not a management failure alone but the relentless price pressure branded generics face from unbranded generics and domestic players with lower cost structures. One strong quarter is encouraging; reversing a structural trend is harder.
The name change. NIL has 120 days from closing to shed the Novartis name and adopt a new corporate identity. Brand power in Indian pharma is partly product brand, partly company brand. Doctors prescribe Voveran because they trust the name behind it. The five-year distribution deal and the Tegrital trademark licence directly address this — product continuity is contractually protected — but the corporate rebrand still carries execution risk. Trust migrates at the pace of sales-force relationships, not regulatory filings.
Float and liquidity. With the promoter group holding 70.68% and public shareholders at ~29.32%, the stock has limited float. Thin trading volumes can make the share price volatile and complicate any future exit — whether through a strategic sale, a secondary PE deal, or a reconstructed entity's IPO.
PE's clock. ChrysCapital plans to deploy Fund X over the next three to four years, with several transactions already in progress. PE funds have exit horizons. The value ChrysCapital can realise at exit depends on whether NIL's revenue trajectory genuinely improves, or whether buyers at that point are simply acquiring the same stagnant business at a later date and a higher multiple.
Zoom out and the Novartis India deal is a data point in a clear directional move. Global pharma majors came to India when the domestic market was nascent and MNC brand equity commanded a significant premium. Most no longer have drugs that can effectively compete with Indian companies that produce generics at scale and at lower cost.
The result has been an orderly handover: as products go off-patent, branded generics enter the market, Indian companies acquire the portfolios, and patients benefit from lower prices while the brands survive under new stewardship. What's new about the Novartis India deal is who's sitting on the Indian side of the table. It isn't a Sun Pharma or a Cipla absorbing another company's assets into an existing distribution machine. It's a PE firm taking majority control of a listed entity and announcing it will build a "branded-generics platform" from scratch.
The acquirers have clarified that they do not intend to delist Novartis India but will ensure compliance with the 25% minimum public shareholding norm if required. That commitment keeps NIL in the listed universe — which means its performance will remain visible quarter by quarter.
That structure — PE-owned, domestically focused, built on inherited MNC brand equity — is still relatively novel. Whether it becomes a template depends entirely on one number: does NIL's revenue, stuck near ₹355 crore for two years, move meaningfully forward under new ownership? If it does, every other MNC holding a legacy branded portfolio will have a clear exit path — and a clear buyer type — in mind. If it doesn't, the ₹1,446 crore will look like a premium paid for familiarity that the market had already stopped rewarding.
The next four quarters will say more than the last five years.